Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Dose-Escalation Study of LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD)
Authors not listed
Innostellar Biotherapeutics Co.,Ltd · 2023
Abstract
The goal of this study is to evaluate the safety and efficacy of LX102 gene therapy for nAMD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-15 MST
Cite this
APA
Anonymous. (2023). A Dose-Escalation Study of LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD). <em>Innostellar Biotherapeutics Co.,Ltd</em>. https://clinicaltrials.gov/study/NCT06198413
Vancouver
Anonymous. A Dose-Escalation Study of LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD). Innostellar Biotherapeutics Co.,Ltd. 2023.
BibTeX
@misc{anon2023ADoseE,
title = {A Dose-Escalation Study of LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD)},
author = {Anonymous},
journal = {Innostellar Biotherapeutics Co.,Ltd},
year = {2023},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Ophthalmology 2012
Preprint · OA
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
EyebioKorea, Inc. 2024
Open access · US-GOV
A Randomization, Double-blind, Parallel, Multicenter-Phase 2a Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 2021
Open access · US-GOV
An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Efficacy of LX102-C01 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
Chengdu Origen Biotechnology Co., Ltd. 2023
Open access · US-GOV
A Phase I/II, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Hoffmann-La Roche 2019
Open access · US-GOV
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (LUCERNE)
Novartis 2007
Open access · US-GOV